One of the United Kingdom’s leading equine veterinary surgeons will share the ‘good, the bad and the ugly’ of lameness conditions affecting horses during two events this month. They are the final two online sessions of a successful series from Dechra Veterinary Products, which has brought together equine veterinary professionals from across the UK and Ireland.
Andy Fiske-Jackson, BVSc MVetMed, FHEA, DiplECVS, MRCVS, Deputy Head of the Royal Veterinary College and Senior Lecturer in Equine Surgery will present webinars on May 19 and May 26 at 2 p.m. Eastern.
Registration is via www.dechra.co.uk/events.
Emma Jennings, Equine Brand Manager at Dechra, said: “Dr. Fiske-Jackson will be leading a case-based session looking at the good, the bad and the ugly of digital flexor tendon sheath cases. He’ll also be unravelling the diagnosis and treatment of navicular syndrome, the associated biomechanics and treatment options.
“The feedback from the initial events we held with equine specialist David Bardell was really positive, with attendees appreciating the exploration of some key issues,” Jennings continued.
“We know that Dr Fiske-Jackson’s webinar will be equally useful to equine veterinary professionals looking to understand more about the causes, diagnosis and treatment of these lameness conditions,” she said.
Equine vets are being urged to register for the final two events as spaces are limited. Register by visiting www.dechra.co.uk/events.
May 19 at 2 p.m. Eastern: Digital Flexor Tendon Sheath Cases—the good, the bad and the ugly, with Dr. Andrew Fiske-Jackson, BVSc, MVetMed, DiplECVS, MRCVS
May 26 at 2 p.m. Eastern: Unravelling the Diagnosis and Treatment of Navicular Syndrome, with Dr. Andrew Fiske-Jackson, BVSc, MVetMed, DiplECVS, MRCVS
Dechra Veterinary Products Ltd. is part of Dechra Pharmaceuticals PLC (‘Dechra’) and offers a range of pharmaceutical products and instruments to veterinary practices in the UK and Republic of Ireland. Dechra Veterinary Products specializes in the development and marketing of licensed branded pharmaceuticals in the global veterinary market.
An innovative company, it invests in the development of products and services while providing a high level of support to vets. Dechra’s expertise spans dermatology, endocrinology, equine medicine, ophthalmology, critical care and diet and nutrition. Major brands include: Vetoryl Capsules, for the treatment of canine hyperadrenocorticism (Cushing’s syndrome); Dermatology brands Canaural, Isaderm Gel and Malaseb Shampoo; Felimazole Tablets, for treating feline hyperthyroidism; Equipalazone, the anti-inflammatory and analgesic for equine musculoskeletal disorders and ophthalmic product Isathal.